MSMelisa M. Shah

Melisa M. Shah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Melisa M. Shah has a total of 193 co-authors. Here are the top co-authors by number of shared publications:

  • Brendan Joyce

    Epic Research, Epic Systems Corporation , Verona, Wisconsin , USA

    3 shared publications
  • Danessa Sandmann

    Epic Research, Epic Systems Corporation , Verona, Wisconsin , USA

    3 shared publications
  • Eric Barkley

    Epic Research, Epic Systems Corporation , Verona, Wisconsin , USA

    3 shared publications
  • H. Keipp Talbot

    Vanderbilt University Medical Center Nashville Tennessee USA

    3 shared publications
  • Joseph Deckert

    Epic Research, Epic Systems Corporation , Verona, Wisconsin , USA

    3 shared publications
  • Leora R. Feldstein

    Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia

    3 shared publications

Latest Publications

  • Open Access

    COVID‐19 Antiviral Treatment: Examining Knowledge, Access, Trust in Sources of Information and Willingness to Use Among Essential Workers: A Cross‐Sectional Survey of Cohort Participants

    by Jenae Sanders, Jade James‐Gist, Melisa M. Shah, Nathan Graff, Olivia Almendares, Tiffany Israel, Yuwei Zhu, Bryan Blette, Sarah Hamid, Hope King, et al.

    Background and Aims: Despite evidence of effectiveness, oral antivirals for COVID‐19 are underused, with significant variation across populations. This study examines COVID‐19 treatment awareness, knowledge, access, trusted sources, and willingness to use among diverse essential workers in Tennessee during May 18, 2023–June 1, 2024. Methods: Participants enrolled in a prospective community cohort study completed an enrollment survey on demographics, medical history, and vaccination status. Quarterly cross‐sectional surveys assessed knowledge, awareness, access, trust, and willingness to use COVID‐19 antivirals. Knowledge, access, and trust were measured using five‐point Likert‐type scales, and knowledge was converted into a score based on number of correct responses. Awareness and willingness were assessed using yes/no/unsure responses. Responses from survey respondents with risk factors for severe COVID‐19 were assessed. Descriptive analyses and χ 2 tests assessed differences across demographic and health characteristics. Multivariable log‐binomial regression modeling was used to estimate unadjusted and adjusted prevalence ratios for key outcomes by demographic and health characteristic with 95% confidence intervals. Results: Of 1289 respondents with risk factors for severe COVID‐19, over 50% were aware of COVID‐19 antivirals; 69% were willing to take antivirals if recommended by their healthcare provider. Adjusted models showed older respondents had higher awareness, knowledge, access and trust in doctors. Black non‐Hispanic respondents, those with lower education, and those with fewer vaccinations were less likely to be aware of antivirals, answer knowledge questions correctly, or report willingness to use antivirals if recommended. Hispanic respondents reported less awareness, knowledge, and lower trust in doctors as a good source of information about COVID‐19 antivirals. Conclusion: Although willingness to use COVID‐19 antivirals was relatively high among diverse essential workers with risk factors for severe COVID‐19, there was variation based on demographic and health factors. This study identifies key gaps, providing a foundation for developing new approaches to improve access to antiviral treatments.

  • Open Access

    Melioidosis Complicated by Native Valve Endocarditis in a Traveler Returning From Thailand to the United States

    by Akash Gupta, Roumen Iordanov, Antonie Auguste, Julianna Van Enk, Melisa M Shah, Brian T Richardson, Jay E Gee, Mindy G Elrod, Taylor Paisie, Christopher A Gulvik, et al.

    Endocarditis from melioidosis is rarely reported; only 14 cases have been reported in the literature. We present a fatal case of native aortic valve endocarditis due to Burkholderia pseudomallei complicated by embolic stroke and subdural empyema that occurred in a traveler who returned from Thailand to the United States.

  • Preventable Differences in Recommended Outpatient COVID-19 Treatment Among Adults With COVID-19 in the United States

    by Mariela Bournigal-Feliciano, Nathan Graff, Emilia H. Koumans, Melisa M. Shah, Makhabele N. Woolfork, Natasha B. Lunsford, Hope King, Pragna Patel, Melissa B. Hagen, Michael D. Kappelman, et al.

    Background: The COVID-19 pandemic exposed differences in health care outcomes, including the prescription of COVID-19 antiviral medications. This analysis aimed to describe prescribing patterns in outpatient COVID-19 treatment and assess factors that contributed to these differences. Methods: A cross-sectional analysis was conducted using electronic health record data from August 2022 through March 2024 from health care institutions participating in PCORnet, ® the National Patient-Centered Clinical Research Network. Descriptive statistics were used to characterize COVID-19 outpatients eligible for treatment, and regression models were used to calculate adjusted prevalence ratios (aPR) of prescribed COVID-19 outpatient treatment. Interaction terms assessed the interactions between race and ethnicity and the combined comorbidity index (CCI), age and sex, and age and race and ethnicity. Results: Of 1,247,420 patients eligible for COVID-19 treatment, 334,947 (26.9%) were prescribed outpatient treatment. In adjusted analyses, compared with White patients, all other racial and ethnic groups had lower aPR for treatment (aPRs:0.89–0.99), except patients who reported being multiracial (aPR:1.00; 95% CI: 0.93–1.08). Those aged 65–74 were prescribed treatment more often (aPR: 1.13; 95% CI: 1.12–1.13) compared with patients aged 20–49. Patients with a CCI of 1–3 and ≥4 were prescribed treatment less often (aPR: 0.99, 95% CI: 0.97–1.01 and aPR: 0.91, 95% CI: 0.89–0.94, respectively), compared with those with a CCI of ≤0. These differences were sustained when considering the interactions between race and age and race and CCI. Conclusions: We found differences in recommended outpatient treatment by several sociodemographic variables. Addressing COVID-19 prescription barriers is essential to slow preventable differences from unmet COVID-19 outpatient care.


  • Open Access

    COVID-19 Antiviral Treatment: Examining Knowledge, Access, Trust in Sources of information and Willingness to Use Among Essential Workers

    by Jenae Sanders, Jade James-Gist, Melisa Shah, Nathan Graff, Olivia Almendares, Tiffany Israel, Yuwei Zhu, Bryan Blette, Sarah Hamid, Hope King, et al.

    Objective: Despite evidence of effectiveness, oral antivirals for COVID-19 are underused, with significant variation across populations. This study examines COVID-19 treatment awareness, knowledge, access, trusted sources, and willingness to use among essential workers in Tennessee during February 21, 2023 – June 1, 2024. Methods: Participants enrolled in a prospective cohort study completed a questionnaire on demographics, medical history, and vaccination status. Follow-up surveys assessed COVID-19 antiviral treatment awareness, knowledge, access, trust, and willingness to receive. Responses are described for respondents with risk factors for severe COVID-19, overall and by subgroup. Multivariable log-binomial regression modeling was used to assess the relationship between demographic and health characteristics and key survey outcomes. Results: Of 1,289 respondents with risk factors for severe COVID-19, over 50% were aware of COVID-19 antivirals; 69% were willing to take antivirals if recommended by their healthcare provider. Adjusted models showed older respondents had higher awareness, knowledge, access and trust in doctors. Black non-Hispanic respondents, those with lower education, and those with fewer vaccinations were less likely to be aware of antivirals, answer knowledge questions correctly, or report willingness to use antivirals if recommended. Hispanic respondents reported less awareness, knowledge, and lower trust in doctors as a good source of information about COVID-19 antivirals. Conclusion: Although willingness to use COVID-19 antivirals was relatively high among essential workers with risk factors for severe COVID-19, there was variation based on demographic and health factors. This study identifies key gaps, providing a foundation for developing new approaches to improve access to antiviral treatments.

  • Open Access

    Long-Term Symptoms Associated With SARS-CoV-2 Infection Among Blood Donors

    by Melisa M. Shah, Bryan R. Spencer, Jade James-Gist, James M. Haynes, Leora R. Feldstein, Susan L. Stramer, Jefferson M. Jones, Sharon H. Saydah

    Long-term symptoms, lasting more than 4 weeks after acute COVID-19 disease, are an important consequence of SARS-CoV-2 infection. These symptoms, referred to as post–COVID-19 conditions, can significantly reduce quality of life but may not be systematically diagnosed or documented. Prevalence estimates for post–COVID-19 conditions vary widely across studies depending on the definition and method of assessment.1-6 A meta-analysis reported the pooled global prevalence of post–COVID-19 conditions to be 43% among those with a confirmed COVID-19 diagnosis.6 However, prior studies have often lacked a non–SARS-CoV-2–infected control population to distinguish background prevalence of symptoms from the effect of COVID-19 disease. A more robust understanding is needed of how long-term symptoms after SARS-CoV-2 infection differ from baseline levels and how to distinguish them from the physical and mental impacts of the pandemic.


  • Open Access

    Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19

    by Melisa M Shah, Brendan Joyce, Ian D Plumb, Sam Sahakian, Leora R Feldstein, Eric Barkley, Mason Paccione, Joseph Deckert, Danessa Sandmann, Melissa Briggs Hagen, et al.

    Among adults at risk for severe coronavirus disease 2019 (COVID-19), the lowest hospitalization rate was among those who received nirmatrelvir-ritonavir after 3 or more messenger RNA vaccine doses (adjusted hazard ratio, 0.22; 95% confidence interval, .19–.24). Eligible adults, including those previously vaccinated, should be considered for COVID-19 antiviral treatment.


  • Open Access

    Bacterial and viral infections among adults hospitalized with COVID‐19, COVID‐NET, 14 states, March 2020–April 2022

    by Melisa M. Shah, Kadam Patel, Jennifer Milucky, Christopher A. Taylor, Arthur Reingold, Isaac Armistead, James Meek, Evan J. Anderson, Andy Weigel, Libby Reeg, et al.

    Background: Bacterial and viral infections can occur with SARS‐CoV‐2 infection, but prevalence, risk factors, and associated clinical outcomes are not fully understood.Methods: We used the Coronavirus Disease 2019‐Associated Hospitalization Surveillance Network (COVID‐NET), a population‐based surveillance system, to investigate the occurrence of bacterial and viral infections among hospitalized adults with laboratory‐confirmed SARS‐CoV‐2 infection between March 2020 and April 2022. Clinician‐driven testing for bacterial pathogens from sputum, deep respiratory, and sterile sites were included. The demographic and clinical features of those with and without bacterial infections were compared. We also describe the prevalence of viral pathogens including respiratory syncytial virus, rhinovirus/enterovirus, influenza, adenovirus, human metapneumovirus, parainfluenza viruses, and non‐SARS‐CoV‐2 endemic coronaviruses.Results: Among 36 490 hospitalized adults with COVID‐19, 53.3% had bacterial cultures taken within 7 days of admission and 6.0% of these had a clinically relevant bacterial pathogen. After adjustment for demographic factors and co‐morbidities, bacterial infections in patients with COVID‐19 within 7 days of admission were associated with an adjusted relative risk of death 2.3 times that of patients with negative bacterial testing. Staphylococcus aureus and Gram‐negative rods were the most frequently isolated bacterial pathogens. Among hospitalized adults with COVID‐19, 2766 (7.6%) were tested for seven virus groups. A non‐SARS‐CoV‐2 virus was identified in 0.9% of tested patients.Conclusions: Among patients with clinician‐driven testing, 6.0% of adults hospitalized with COVID‐19 were identified to have bacterial coinfections and 0.9% were identified to have viral coinfections; identification of a bacterial coinfection within 7 days of admission was associated with increased mortality.


  • Open Access

    Paxlovid associated with decreased hospitalization rate among adults with COVID-19 — United States, April–September 2022

    by Melisa M. Shah, Brendan Joyce, Ian D. Plumb, Sam Sahakian, Leora R. Feldstein, Eric Barkley, Mason Paccione, Joseph Deckert, Danessa Sandmann, Jacqueline L. Gerhart, et al.


  • Top Cited Papers
    Open Access

    Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 — United States, April–September 2022

    by Melisa M. Shah, Brendan Joyce, Ian D. Plumb, Sam Sahakian, Leora R. Feldstein, Eric Barkley, Mason Paccione, Joseph Deckert, Danessa Sandmann, Jacqueline L. Gerhart, et al.

    This report describes how eligible adults prescribed Paxlovid were 51% less likely to be hospitalized with COVID-19, regardless of vaccination status.


  • Open Access

    Occupations Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Vaccination, US Blood Donors, May 2021–December 2021

    by Melisa M Shah, Bryan R Spencer, Leora R Feldstein, James M Haynes, Tina J Benoit, Sharon H Saydah, Matthew R Groenewold, Susan L Stramer, Jefferson M Jones

    Background: There are limited data on the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States by occupation. We identified occupations at higher risk for prior SARS-CoV-2 infection as defined by the presence of infection-induced antibodies among US blood donors.Methods: Using a nested case-control study design, blood donors during May–December 2021 with anti-nucleocapsid (anti-N) testing were sent an electronic survey on employment status, vaccination, and occupation. The association between previous SARS-CoV-2 infection and occupation-specific in-person work was estimated using multivariable logistic regression adjusting for sex, age, month of donation, race and ethnicity, education, vaccination, and telework.Results: Among 85 986 included survey respondents, 9504 (11.1%) were anti-N reactive. Healthcare support (20.3%), protective service (19.9%), and food preparation and serving related occupations (19.7%) had the highest proportion of prior infection. After adjustment, prior SARS-CoV-2 infection was associated with healthcare practitioners (adjusted odds ratio [aOR], 2.10; 95% confidence interval [CI], 1.74–2.54) and healthcare support (aOR, 1.82; 95% CI, 1.39–2.40) occupations compared with computer and mathematical occupations as the referent group. Lack of coronavirus disease 2019 vaccination (aOR, 16.13; 95% CI, 15.01–17.34) and never teleworking (aOR, 1.17; 95% CI, 1.05–1.30) were also independently associated with prior SARS-CoV-2 infection. Construction and extraction occupations had the highest proportion of unvaccinated workers (30.5%).Conclusions: Workers in healthcare, protective services, and food preparation had the highest prevalence of prior SARS-CoV-2 infection. Occupational risks for SARS-CoV-2 infection remained after adjusting for vaccination, telework, and demographic factors. These findings underscore the need for mitigation measures and personal protection in healthcare settings and other workplaces.